Patient demographics
| . | G-BM (n = 28) . | G-PBSC (n = 29) . | P . |
|---|---|---|---|
| Age (y) | 44 (16-60) | 46 (24-58) | .2 |
| High risk (%) | 9 (32) | 11 (38) | .6 |
| Diagnosis | |||
| AA | 1/0 | 0/0 | |
| AL | 8/1 | 1/4 | |
| CML | 2/1 | 8/1 | |
| MDS | 0/5 | 0/4 | |
| MM | 4/0 | 4/0 | |
| MF | 0/0 | 1/0 | |
| NHL/CLL | 4/2 | 4/2 | |
| CMV | .7 | ||
| D−R− (%) | 5 (18) | 3 (10) | |
| D−R+ (%) | 7 (25) | 5 (17) | |
| D+R− (%) | 3 (11) | 4 (14) | |
| D+R+ (%) | 13 (46) | 17 (59) | |
| Sex match | .4 | ||
| M to M (%) | 5 (18) | 5 (17) | |
| M to F (%) | 10 (36) | 6 (21) | |
| F to M (%) | 8 (29) | 8 (28) | |
| F to F (%) | 5 (19) | 10 (35) | |
| PF to M (%) | 5 (18) | 4 (14) | |
| Conditioning | .3 | ||
| CYTBI (%) | 5 (18) | 5 (17) | |
| BUCY (%) | 19 (68) | 21 (72) | |
| Other (%) | 4 (14) | 3 (10) |
| . | G-BM (n = 28) . | G-PBSC (n = 29) . | P . |
|---|---|---|---|
| Age (y) | 44 (16-60) | 46 (24-58) | .2 |
| High risk (%) | 9 (32) | 11 (38) | .6 |
| Diagnosis | |||
| AA | 1/0 | 0/0 | |
| AL | 8/1 | 1/4 | |
| CML | 2/1 | 8/1 | |
| MDS | 0/5 | 0/4 | |
| MM | 4/0 | 4/0 | |
| MF | 0/0 | 1/0 | |
| NHL/CLL | 4/2 | 4/2 | |
| CMV | .7 | ||
| D−R− (%) | 5 (18) | 3 (10) | |
| D−R+ (%) | 7 (25) | 5 (17) | |
| D+R− (%) | 3 (11) | 4 (14) | |
| D+R+ (%) | 13 (46) | 17 (59) | |
| Sex match | .4 | ||
| M to M (%) | 5 (18) | 5 (17) | |
| M to F (%) | 10 (36) | 6 (21) | |
| F to M (%) | 8 (29) | 8 (28) | |
| F to F (%) | 5 (19) | 10 (35) | |
| PF to M (%) | 5 (18) | 4 (14) | |
| Conditioning | .3 | ||
| CYTBI (%) | 5 (18) | 5 (17) | |
| BUCY (%) | 19 (68) | 21 (72) | |
| Other (%) | 4 (14) | 3 (10) |
AA indicates aplastic anemia; AL, acute leukemia; MDS, myelodysplasia; MM, multiple myeloma; MF, myelofibrosis; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; D, donor; R, recipient; M, male; F, female; PF, parous female; CYTBI, 120 mg/kg cyclophosphamide + total body irradiation (12 Gy, 6 fractions); BUCY, 16 mg/kg busulfan + 120 mg/kg cyclophosphamide.